Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short term Debt (2020 - 2021)

Lineage Cell Therapeutics (LCTX) has 4 years of Short term Debt data on record, last reported at $523000.0 in Q1 2021.

  • For Q1 2021, Short term Debt changed N/A year-over-year to $523000.0; the TTM value through Mar 2021 reached $523000.0, changed N/A, while the annual FY2020 figure was $523000.0, N/A changed from the prior year.
  • Short term Debt reached $523000.0 in Q1 2021 per LCTX's latest filing, roughly flat from $523000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $523000.0 in Q2 2020 and bottomed at $523000.0 in Q2 2020.